Global Glomerulonephritis Market: Major Trends Reshaping the Future of the Industry

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Glomerulonephritis Industry Market Size Be by 2025?
The market for glomerulonephritis has experienced consistent expansion recently, projected to increase its valuation from $11.06 billion in 2024 to $11.61 billion the following year, reflecting a 4.9% compound annual growth rate. This historical upward trend is largely driven by several factors, including the increasing frequency of renal ailments, the widespread occurrence of infections like post-streptococcal glomerulonephritis, heightened investment in research and development activities, a greater number of kidney failure cases surfacing, and broader public understanding about kidney-related illnesses.

What's the Long-Term Growth Forecast for the Glomerulonephritis Market Size Through 2029?
The overall valuation of the glomerulonephritis market anticipates consistent expansion over the coming years, projected to attain a value of $14.03 billion by 2029, driven by a compound annual growth rate (CAGR) of 4.9%. This forward momentum during the projection timeframe stems from several contributing factors, such as the growing prevalence of diabetes, demographic shifts towards an older populace, escalating healthcare spending, a rising patient count undergoing dialysis procedures, and the increased incidence of autoimmune disorders. Key developments expected to shape this period include the introduction of recently developed treatments and therapeutic options, progress in diagnostic tools, the emergence of innovative remedies, heightened collaboration among industry players, and the utilization of intravenous immunoglobulin therapy.

View the full report here:
https://www.thebusinessresearchcompany.com/report/glomerulonephritis-global-market-report

What Are the Key Growth Drivers Fueling the Glomerulonephritis Market Expansion?
Anticipation surrounds the expansion of the glomerulonephritis market, which stands to benefit significantly from the increasing incidence of kidney ailments. These conditions encompass various problems impacting renal architecture or performance, thereby compromising the body's ability to filter blood, eliminate wastes, and manage fluid levels. Contributing elements to the surge in kidney disorders include demographic shifts toward older age groups, escalating occurrences of long-term illnesses like hypertension and diabetes, alongside contemporary lifestyle patterns. Such kidney problems directly fuel glomerulonephritis through the initiation of immune system irregularities, persistent inflammatory processes, or physical harm to the kidney structures, ultimately resulting in diminished filtration capacity and organ function. To illustrate this, data published in December 2024 by the Australian Institute of Health and Welfare, a governmental body in Australia, highlighted that mortality rates associated with chronic kidney disease (CKD) saw upticks of 4.2% in 2021 and 6.2% in 2022. Furthermore, during the 2021-22 period, approximately two million hospital admissions in Australia were attributed to CKD, accounting for 18% of all inpatient stays. Consequently, the escalating frequency of kidney diseases is projected to boost the overall growth trajectory of the glomerulonephritis market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21193&type=smp

What Are the Key Trends Driving Glomerulonephritis Market Growth?
Leading entities within the glomerulonephritis sector are concentrating efforts on engineering sophisticated therapeutic options that forgo immunosuppression, thereby tackling inadequately addressed patient requirements and enhancing clinical success. Therapies categorized as non-immunosuppressive operate by managing the condition without diminishing the body's natural defense mechanisms. To illustrate, the US pharmaceutical firm Travere Therapeutics Inc. secured Food and Drug Administration (FDA) endorsement in September 2024 for FILSPARI (sparsentan), indicated for patients suffering from IgA nephropathy, a specific kidney ailment. Remarkably, this medication stands out as the sole non-immunosuppressive agent demonstrating a substantial deceleration in the loss of kidney function among affected individuals. The regulatory clearance of FILSPARI signifies a crucial advance in managing IgA nephropathy, recognized as the most prevalent form of primary glomerulonephritis, presenting a fresh pathway for individuals whose prior therapeutic selections were scarce. This authorization underscores Travere's dedication to elevating the quality of life for those afflicted with renal disorders.

How Is the Glomerulonephritis Market Segmented?
The glomerulonephritismarket covered in this report is segmented -

1) By Type: Acute Glomerulonephritis; Chronic Glomerulonephritis
2) By Diagnosis: Urine And Blood Tests; Imaging Tests; Kidney Biopsy; Other Diagnosis
3) By Treatment: Medication; Surgery; Dialysis; Other Treatments
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Other Distribution Channels
5) By End-User: Hospitals; Specialty Clinics; Other End-Users

Subsegments:
1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis; IgA Nephropathy; Lupus Nephritis; Rapidly Progressive Glomerulonephritis (RPGN); Goodpasture Syndrome
2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS); Membranous Nephropathy; Minimal Change Disease; Alport Syndrome; Diabetic Nephropathy; Hypertensive Nephrosclerosis

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21193&type=smp

Which Companies Are Leading the Charge in Glomerulonephritis Market Innovation?
Major companies operating in the glomerulonephritis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Asahi Kasei Medical Co. Ltd., Boehringer Ingelheim International GmbH, DaVita Inc., Biogen Inc., Merit Medical Systems Inc., Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., NovelMed Therapeutics Inc.

Which Regions Are Leading the Global Glomerulonephritis Market in Revenue?
North America was the largest region in the glomerulonephritis market in 2024. The regions covered in the glomerulonephritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21193

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.